These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23856914)

  • 1. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
    Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
    J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.
    Hennessy EJ; Moore KJ
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):247-54. PubMed ID: 23743768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
    Aslesh T; Yokota T
    Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides as therapeutics for hyperlipidaemias.
    Crooke RM
    Expert Opin Biol Ther; 2005 Jul; 5(7):907-17. PubMed ID: 16018737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecule of the Month. Mipomersem sodium.
    Drug News Perspect; 2008 Oct; 21(8):464. PubMed ID: 19034352
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacology of Antisense Drugs.
    Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
    Ricotta DN; Frishman W
    Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense therapy and emerging applications for the management of dyslipidemia.
    Toth PP
    J Clin Lipidol; 2011; 5(6):441-9. PubMed ID: 22108147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies to control lipid metabolism: can the antisense drug mipomersen fulfill the unmet need?
    Merk D; Schubert-Zsilavecz M
    Future Med Chem; 2012 Sep; 4(14):1773-5. PubMed ID: 23043473
    [No Abstract]   [Full Text] [Related]  

  • 12. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing therapeutics in SMN2 and APOB.
    Khoo B; Krainer AR
    Curr Opin Mol Ther; 2009 Apr; 11(2):108-15. PubMed ID: 19330716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver histology during Mipomersen therapy for severe hypercholesterolemia.
    Hashemi N; Odze RD; McGowan MP; Santos RD; Stroes ESG; Cohen DE
    J Clin Lipidol; 2014; 8(6):606-611. PubMed ID: 25499943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
    Sahebkar A; Watts GF
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonstatin Therapy for Dyslipidemia.
    Ahmed HM; Nissen SE
    Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
    [No Abstract]   [Full Text] [Related]  

  • 20. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.